<PAPER><mode2 name='PMC2806632' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>BMJ</journal-id><journal-id journal-id-type='publisher-id'>bmj</journal-id><journal-title-group><journal-title>BMJ : British Medical Journal</journal-title></journal-title-group><issn pub-type='ppub'>0959-8138</issn><issn pub-type='epub'>1468-5833</issn><publisher><publisher-name>BMJ Publishing Group Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>2806632</article-id><article-id pub-id-type='pmid'>20068258</article-id><article-id pub-id-type='publisher-id'>chen684415</article-id><article-id pub-id-type='doi'>10.1136/bmj.b5465</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research</subject></subj-group><subj-group subj-group-type='hw-coll-titles'><subject>Epidemiologic studies</subject><subject>Drugs: cardiovascular system</subject><subject>Memory disorders (neurology)</subject><subject>Drugs: CNS (not psychiatric)</subject><subject>Stroke</subject><subject>Hypertension</subject><subject>Memory disorders (psychiatry)</subject><subject>Drugs: musculoskeletal and joint diseases</subject><subject>Diabetes</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis</s></article-title></title-group><contrib-group><contrib contrib-type='author' corresp='no'><name><surname>Li</surname><given-names>Nien-Chen</given-names></name><role>statistician</role><xref rid='aff1' ref-type='aff'>1</xref><xref rid='aff2' ref-type='aff'>2</xref></contrib><contrib contrib-type='author' corresp='no'><name><surname>Lee</surname><given-names>Austin</given-names></name><role>senior statistician</role><xref rid='aff2' ref-type='aff'>2</xref><xref rid='aff3' ref-type='aff'>3</xref></contrib><contrib contrib-type='author' corresp='no'><name><surname>Whitmer</surname><given-names>Rachel A</given-names></name><role>research epidemiologist</role><xref rid='aff4' ref-type='aff'>4</xref></contrib><contrib contrib-type='author' corresp='no'><name><surname>Kivipelto</surname><given-names>Miia</given-names></name><role>associate professor</role><xref rid='aff5' ref-type='aff'>5</xref></contrib><contrib contrib-type='author' corresp='no'><name><surname>Lawler</surname><given-names>Elizabeth</given-names></name><role>epidemiologist</role><xref rid='aff6' ref-type='aff'>6</xref></contrib><contrib contrib-type='author' corresp='no'><name><surname>Kazis</surname><given-names>Lewis E</given-names></name><role>professor</role><xref rid='aff1' ref-type='aff'>1</xref><xref rid='aff2' ref-type='aff'>2</xref></contrib><contrib contrib-type='author' corresp='yes'><name><surname>Wolozin</surname><given-names>Benjamin</given-names></name><role>professor</role><xref rid='aff2' ref-type='aff'>2</xref><xref rid='aff7' ref-type='aff'>7</xref></contrib><aff id='aff1'><label>1</label>Center for the Assessment of Pharmaceutical Practices and Pharmaceutical Assessment, Management and Policy Program, Department of Health Policy and Management, Boston University School of Public Health, Boston, MA, USA</aff><aff id='aff2'><label>2</label>Center for Health Quality Outcomes and Economic Research, Veteran Affairs Medical Center, Bedford, MA</aff><aff id='aff3'><label>3</label>Department of Surgery, Massachusetts General Hospital, Boston, MA</aff><aff id='aff4'><label>4</label>Division of Research, Epidemiology, Etiology and Prevention, Kaiser Permanente, Oakland, CA, USA</aff><aff id='aff5'><label>5</label>Aging Research Center, Karolinska Institute, Stockholm, Sweden</aff><aff id='aff6'><label>6</label>MAVERIC, VA Cooperative Studies Program, Boston, MA</aff><aff id='aff7'><label>7</label>Department of Pharmacology and Department of Neurology, Boston University School of Medicine, Boston, MA 02118-2526, USA</aff></contrib-group><author-notes><corresp>Correspondence to: <email>bwolozin@bu.edu</email></corresp></author-notes><pub-date pub-type='collection'><year>2010</year></pub-date><pub-date pub-type='ppub'><year>2010</year></pub-date><pub-date pub-type='epub'><day>12</day><month>1</month><year>2010</year></pub-date><volume>340</volume><elocation-id>b5465</elocation-id><history><date date-type='accepted'><day>26</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>© Li et al 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Li et al</copyright-holder><license license-type='open-access'><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by-nc/2.0/'>http://creativecommons.org/licenses/by-nc/2.0/</ext-link>  and  <ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by-nc/2.0/legalcode'>http://creativecommons.org/licenses/by-nc/2.0/legalcode</ext-link>.</license-p></license></permissions><self-uri xlink:type='simple' xlink:title='pdf' xlink:href='bmj.b5465_default.pdf'></self-uri><abstract><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1><bold>Objective</bold> To investigate whether angiotensin receptor blockers protect against Alzheimer’s disease and dementia or reduce the progression of both diseases.</s></p><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><bold>Design</bold> Prospective cohort analysis.</s></p><p><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><bold>Setting</bold> Administrative database of the US Veteran Affairs, 2002-6.</s></p><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1><bold>Population</bold> 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease.</s></p><p><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1><bold>Main outcome measures</bold> Time to incident Alzheimer’s disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the “cardiovascular comparator”) over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer’s disease or dementia.</s></p><p><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1><bold>Results</bold> Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer’s disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97).</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49).</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Minor differences were shown in mean systolic and diastolic blood pressures between the groups.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Similar results were observed for Alzheimer’s disease.</s></p><p><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1><bold>Conclusions</bold> Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer’s disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.</s></p></abstract></article-meta><notes notes-type='data-supplement'><label>Web Extra</label><title>Extra material supplied by the author</title><supplementary-material content-type='local-data'><caption><p>Unadjusted rates for incident Alzheimer’s disease and dementia</p></caption><media mime-subtype='pdf' mimetype='application' xlink:href='chen684415.wt1_default.pdf'><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type='local-data'><caption><p>Unadjusted rates for admission to a nursing home and death</p></caption><media mime-subtype='pdf' mimetype='application' xlink:href='chen684415.wt2_default.pdf'><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type='local-data'><caption><p>Follow-up times for participants</p></caption><media mime-subtype='pdf' mimetype='application' xlink:href='chen684415.wt3_default.pdf'><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type='local-data'><caption><p>Usage patterns of individual angiotensin receptor blockers</p></caption><media mime-subtype='pdf' mimetype='application' xlink:href='chen684415.wt4_default.pdf'><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type='local-data'><caption><p>Additive effects</p></caption><media mime-subtype='pdf' mimetype='application' xlink:href='chen684415.wt5_default.pdf'><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></front><body><sec sec-type='intro'><title>Introduction</title><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Dementia, including Alzheimer’s disease, is one of the major threats to public health as people age.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Dementia is also an important economic cost to society because affected people may spend extended periods in nursing homes.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The causes of dementia, and Alzheimer’s disease in particular, are complex, but evidence increasingly points to three main risk factors—age, the accumulation of amyloid β in the brain, and the deterioration of the cardiovascular system.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cardiovascular dysfunction is also strongly related to other forms of dementia.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Studies have found that cardiovascular risk factors in mid-life, such as hypercholesterolaemia, hypertension, and diabetes contribute to the development of dementia.<xref rid='ref1' ref-type='bibr'>1</xref><xref rid='ref2' ref-type='bibr'>2</xref><xref rid='ref3' ref-type='bibr'>3</xref><xref rid='ref4' ref-type='bibr'>4</xref><xref rid='ref5' ref-type='bibr'>5</xref></s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Drugs used to treat these risk factors may also reduce the incidence of dementia.<xref rid='ref6' ref-type='bibr'>6</xref><xref rid='ref7' ref-type='bibr'>7</xref><xref rid='ref8' ref-type='bibr'>8</xref><xref rid='ref9' ref-type='bibr'>9</xref><xref rid='ref10' ref-type='bibr'>10</xref><xref rid='ref11' ref-type='bibr'>11</xref></s></p><p><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Pharmacotherapy targeting the renin-angiotensin system is one of the most effective means of reducing hypertension and cardiovascular morbidity.<xref rid='ref12' ref-type='bibr'>12</xref><xref rid='ref13' ref-type='bibr'>13</xref></s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Renin is a protease that cleaves angiotensinogen to produce angiotensin I, which is then cleaved by angiotensin converting enzyme to produce the bioactive peptide angiotensin II.<xref rid='ref14' ref-type='bibr'>14</xref></s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Angiotensin II binds to multiple receptors, with the AT1 and AT2 receptors being the best studied and most abundant angiotensin II receptors in the vasculature.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Both receptors are present in brain and vasculature.<xref rid='ref15' ref-type='bibr'>15</xref></s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> They seem to function in opposition.<xref rid='ref16' ref-type='bibr'>16</xref></s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The mechanism of action of AT2 receptors remains to be fully elucidated, but in the rat the receptors inhibit endothelial cell proliferation and promote axonal regeneration.<xref rid='ref17' ref-type='bibr'>17</xref><xref rid='ref18' ref-type='bibr'>18</xref></s></p><p><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Multiple studies have shown that angiotensin converting enzyme inhibitors prevent the action of angiotensin II and are the most effective agents for lowering blood pressure.<xref rid='ref12' ref-type='bibr'>12</xref><xref rid='ref13' ref-type='bibr'>13</xref></s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Their efficacy has led to this class of drugs being designated as a primary treatment for hypertension.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These drugs are also associated with lower rates of congestive heart failure, myocardial ischaemia, renal disease, and death than hypertensive drugs acting through other mechanisms.<xref rid='ref12' ref-type='bibr'>12</xref><xref rid='ref13' ref-type='bibr'>13</xref></s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Two small studies found that angiotensin converting enzyme inhibitors reduced rates of cognitive decline.<xref rid='ref19' ref-type='bibr'>19</xref><xref rid='ref20' ref-type='bibr'>20</xref></s></p><p><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Drugs that selectively inhibit the AT1 receptor are termed angiotensin receptor blockers.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These drugs reduce blood pressure and protect against cardiovascular outcomes such as myocardial infarction and atrial fibrillation although with slightly less efficacy than angiotensin converting enzyme inhibitors.<xref rid='ref12' ref-type='bibr'>12</xref><xref rid='ref13' ref-type='bibr'>13</xref></s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Angiotensin receptor blockers also protect against diabetes, possibly with greater efficacy than angiotensin converting enzyme inhibitors.<xref rid='ref21' ref-type='bibr'>21</xref><xref rid='ref22' ref-type='bibr'>22</xref><xref rid='ref23' ref-type='bibr'>23</xref></s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The Valsartan Heart Failure Trial (Val-HeFT) suggested that angiotensin receptor blockers and angiotensin converting enzyme inhibitors exhibit added benefit for cardiovascular outcomes when used in combination, but this was not observed in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) study.<xref rid='ref24' ref-type='bibr'>24</xref><xref rid='ref25' ref-type='bibr'>25</xref></s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> An increasing number of studies have shown a relation between angiotensin receptor blockers and preservation of cognitive function.<xref rid='ref26' ref-type='bibr'>26</xref></s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Studies in both animals and humans found that angiotensin receptor blockers help to preserve cognitive function through a mechanism that is independent of the antihypertensive effects.<xref rid='ref27' ref-type='bibr'>27</xref><xref rid='ref28' ref-type='bibr'>28</xref><xref rid='ref29' ref-type='bibr'>29</xref><xref rid='ref30' ref-type='bibr'>30</xref><xref rid='ref31' ref-type='bibr'>31</xref></s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Comprehensive summaries on the role of the renin-angiotensin system in Alzheimer’s disease and the effects on cognitive function of drugs that inhibit the renin-angiotensin system have been reviewed.<xref rid='ref32' ref-type='bibr'>32</xref><xref rid='ref33' ref-type='bibr'>33</xref></s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> On the basis of these data the effect of angiotensin receptor blockers and angiotensin converting enzyme inhibitors on dementia outcomes should be evaluated.</s></p><p><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>We investigated whether angiotensin receptor blockers protect against dementia and Alzheimer’s disease and reduce the progression of these diseases in a large population with uniform healthcare coverage.</s></p></sec><sec sec-type='methods'><title>Methods</title><p><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>This study used information from the Veterans health system decision support system database, which contains records on about 4.5 million people annually in the US Veterans Affairs health system from fiscal year 2002 (1 October 2001) to end of fiscal year 2006 (30 September 2006); over the five years of the study the records totalled about 7.3 million people.<xref rid='ref34' ref-type='bibr'>34</xref></s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For studies of incident Alzheimer’s disease and dementia we used records from the first year of the database, fiscal year 2002, as a baseline to ensure that participants were free of these diseases for at least one year, and we restricted the analytical part of the study to fiscal years 2003-6.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The sample sizes were more than 11 500 for the angiotensin receptor blockers group, more than 91 000 for the lisinopril group, and more than 696 000 for the cardiovascular comparator group; see web extra table 1 on bmj.com.</s></p><p><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>We included adults aged 65 or more as of 1 October 2002.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Disease codes are those used in ICD-9 (international classification of diseases, ninth revision).</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The analysis of incidence was restricted to those without a previous diagnosis of Alzheimer’s disease (code 331.0) or dementia (291, 294, 331.0) as judged by an absence of the diagnosis from fiscal year 2002 or up to the point of initiation of the targeted drugs for participants who started taking the drugs after fiscal year 2002.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We restricted the analysis of disease progression to those with an existing diagnosis of Alzheimer’s disease or dementia; only events after the diagnosis of dementia were used for the study of progression.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To establish exclusion criteria we used a floating starting point.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The time to event was measured from the first record of the drug to the occurrence of the event (diagnosis of dementia or Alzheimer’s disease, nursing home admission, or death).</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> For participants lacking events before the end of fiscal year 2006 we defined the time to event as censored.</s></p><sec><title>Comparators and models</title><p><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We examined three cohorts: those taking angiotensin receptor blockers, those taking the angiotensin converting enzyme inhibitor lisinopril, and those taking cardiovascular drugs (drugs with a “CV” designation in the Veterans Affairs formulary, excluding angiotensin receptor blockers, statins, and angiotensin converting enzyme inhibitors), the “cardiovascular comparator.” The lisinopril group represents a comparator group of a similar drug class to that of angiotensin receptor blockers because of shared indications for use.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We specifically selected lisinopril because it is has the largest group of users and longest history of use.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To control for potential biases related to selection of one particular angiotensin converting enzyme inhibitor we also examined a comparator group of the cohort using other angiotensin converting enzyme inhibitors (see fig 3, table 5, and web extra table 5).</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also examined a second group comprising people taking cardiovascular drugs other than angiotensin receptor blockers, the cardiovascular comparator group.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We examined this group because overlap between the site of action of angiotensin converting enzyme inhibitors and angiotensin receptor blockers could mute a potentially beneficial effect of angiotensin receptor blockers.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The cardiovascular comparator group contained people with similar morbidity profiles to that of the angiotensin receptor blocker group but comprised a much broader group of drugs than the angiotensin converting enzyme inhibitor group.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We determined drug use on the basis of two criteria: a drug possession ratio of 80% or greater for the respective drug during the six months after entry into the study, and no exposure to the other study drugs on entry and during the first six months of the study.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We carried out secondary analyses on outcomes in people who switched from angiotensin converting enzyme inhibitors to angiotensin receptor blockers, or vice versa, and the dose-response profiles for angiotensin receptor blocker use.</s></p><p><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The study design used multiple strategies to deal with potential sources of bias.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> To avoid bias due to misclassification we chose cohorts who shared similar health profiles.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Lisinopril and angiotensin receptor blockers are both antihypertensives that modulate angiotensin signalling.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Drugs used by the cardiovascular comparator included β blockers and calcium channel antagonists.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To investigate bias arising from differences in comorbidities and health profiles we compared risk factors for each cohort; these were similar between the groups (table 1).</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Because data on blood pressure were not available from the national Veteran Affairs decision support system database at the time of this study, we determined mean blood pressures for each cohort on the basis of a subsample from the Veterans Affairs health system vertically integrated service network.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We randomly sampled eight values each for systolic and diastolic blood pressure for all the people from each cohort in the Vertically Integrated Service Networks 1, 2, and 3, as a subset analysis and then determined mean systolic and diastolic values for each patient.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To avoid bias from reliance on prescription data we required participants to have a drug possession ratio of 80% or greater.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> High possession ratios imply that patients are using up their drugs in the expected period of time, corresponding with consistent use of the drug.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We examined losses to follow-up for each cohort.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> These did not differ (see web extra table 2).</s></p><p><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Drug use after entry to the study was not restricted, except for the studies of additive effects and switching in which we controlled for exposure to drugs in the other two cohorts after entry into the study.</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Allowing for multiple exposure maintained adequate sample sizes for subgroup analyses and adequate statistical power.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also examined the data on disease progression using a model that excludes polypharmacy after entry to the study; using this approach we obtained similar effects for trend, but the changes did not achieve statistical significance given the inadequate power.</s></p><p><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We examined multiple models.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Firstly, we used age, stroke (code 430-434), hypertension (401-405, and 459.3), cardiovascular disease (429.2, 410-414, 428, 430-438, and 440), and diabetes (250) as covariates.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We removed hypertension when we observed no significant covariation in the multivariate model.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Because angiotensin receptor blockers are often prescribed to people with renal insufficiency, we examined a separate model incorporating renal disease as a covariate; people with renal insufficiency were defined as those with glomerular filtration rates of less than 60 ml/min using a formula defined by the Renal Disease Study Group.<xref rid='ref35' ref-type='bibr'>35</xref></s></p></sec><sec><title>Outcomes</title><p><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>For the analysis of disease progression we studied the time to admission to a nursing home or death.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous clinical studies have successfully used new medical diagnoses or events as proxies for progression of Alzheimer’s disease.</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Time to being admitted to institutional care, for example, has been used as a criterion for evaluation of the clinical efficacy of putative therapeutics for Alzheimer’s disease in multiple prospective clinical trials.<xref rid='ref36' ref-type='bibr'>36</xref><xref rid='ref37' ref-type='bibr'>37</xref><xref rid='ref38' ref-type='bibr'>38</xref><xref rid='ref39' ref-type='bibr'>39</xref></s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Death is also a robust criterion for progression of Alzheimer’s disease.<xref rid='ref36' ref-type='bibr'>36</xref><xref rid='ref38' ref-type='bibr'>38</xref><xref rid='ref40' ref-type='bibr'>40</xref></s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The demonstration of utility for time to admission to institutional care provides good support for the use of these measures as proxies for the progression of Alzheimer’s disease in the current study.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Outcomes of progressive disease were based on the well documented and validated Beneficiary and Identification Records Locator Subsystem files for occurrence of deaths that included date of recorded death, and Veteran Affairs nursing home files for date of being admitted to institutional care.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All files were merged on unique identifiers using scrambled social security numbers and then stripped of these identifiers for confidentiality.</s></p></sec><sec><title>Strategy for analysis</title><p><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We used Cox proportional hazard models to obtain hazard rates between the angiotensin receptor blocker group and comparators, which considers the time to events.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Censoring was defined by three criteria: end of study (30 September 2006); losses to follow-up determined from three database files on clinic visits, diagnoses, and procedures; and death.</s></p></sec><sec><title>Statistical analyses</title><p><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>For all statistical calculations we used SAS version 9.01 software.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Covariates for the Cox proportional hazard models were age, stroke, hypertension, cardiovascular disease, and diabetes.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We carried out data management for missing values on covariates and the outcome variable (time to event).</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> During the main study period (fiscal years 2003-6), we identified 6 867 768 patients from the diagnosis database.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Only 6630 (&lt;0.1%) were missing date of birth.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> By selecting people aged 65 or older on 1 October 2002, those missing date of birth were automatically excluded.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Covariates were coded as present (1) or absent (0) based on diagnoses during the study period.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> If disease codes for a particular condition were missing, we regarded the condition as absent (0).</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Outcomes were defined as time to events, and missing events would appear as time censored either as a result of end of study or losses to follow-up or death (with the exception of the study of progression, where death is defined as an event).</s></p><p><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Point estimates and 95% confidence intervals from Cox proportional hazards models are reported for the adjusted hazard rates.</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Outcomes for each cohort were plotted with a log(−log(time)) <italic>v</italic> log(time) graph.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The curves were parallel, validating the application of the Cox proportional hazards model.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also tested the Weibull model for a sensitivity analysis and obtained similar results.</s></p></sec></sec><sec sec-type='results'><title>Results</title><p><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>After exclusions, 819 491 participants were available for the study of incident Alzheimer’s disease and 799 069 for the study of incident dementia (table 1<xref rid='tbl1' ref-type='table'></xref>).</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The number of participants with existing Alzheimer’s disease for the study of disease progression (admission to a nursing home) was 12 574 (476 in the angiotensin receptor blocker group, 3227 in the lisinopril group, and 8871 in the cardiovascular comparator group, see web extra table 2) and with dementia was 44 601 (1920 in the angiotensin receptor blocker group, 12 064 in the lisinopril group, and 30 617 in the cardiovascular comparator group).</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Overall, 12 879 participants with Alzheimer’s disease (491 in the angiotensin receptor blocker group, 3333 in the lisinopril group, and 9055 in the cardiovascular comparator group) and 45 724 with dementia (1980 in angiotensin receptor blocker group, 12 483 in lisinopril group, and 31 261 in the cardiovascular comparator group) were included in the study of mortality.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean follow-up times are described in web extra table 3.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The characteristics of the groups used for analysis of Alzheimer’s disease and for dementia were similar (table 1).</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The mean age of each group was 74 years, and the participants were largely men (98%).</s></p><p><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The prevalence of general cardiovascular disease and stroke was lower for the angiotensin receptor blocker and lisinopril groups than for the cardiovascular comparator, but the prevalence of diabetes was higher for the angiotensin receptor blocker and lisinopril groups than for the cardiovascular comparator (table 1), which is to be expected in routine care as both angiotensin receptor blockers and lisinopril are frequently prescribed for people with diabetes.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Each of the differences in comorbid illnesses was statistically significant (P&lt;0.001) because of the large number of people in each group.</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Mean systolic and diastolic blood pressures were similar between groups (table 1).</s></p><table-wrap id='tbl1' position='float'><label>Table 1</label><caption><p> Personal details of participants analysed in study. Values are numbers (percentages) unless stated otherwise</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='2' valign='middle' align='left'>Variables</th><th colspan='3' rowspan='1' valign='bottom' align='center'>Alzheimer’s disease (n=819 491)</th><th colspan='3' rowspan='1' valign='bottom' align='center'>Dementia (n=799 069)</th></tr><tr><th colspan='1' rowspan='1' valign='bottom' align='center'>Angiotensin receptor blocker (n=11 703)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Lisinopril (n=93 484)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Cardiovascular comparator (n=714 304)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Angiotensin receptor blocker (n=11 507)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Lisinopril (n=91 164)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Cardiovascular comparator(n=696 398)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' valign='middle' align='left'>Mean (SD) age (years)</td><td colspan='1' rowspan='1' valign='middle' align='center'>74 (5.5)</td><td colspan='1' rowspan='1' valign='middle' align='center'>74 (5.6)</td><td colspan='1' rowspan='1' valign='middle' align='center'>75 (5.9)</td><td colspan='1' rowspan='1' valign='middle' align='center'>74 (5.5)</td><td colspan='1' rowspan='1' valign='middle' align='center'>74 (5.5)</td><td colspan='1' rowspan='1' valign='middle' align='center'>75 (5.9)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'>Race:</td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Hispanic, white</td><td colspan='1' rowspan='1' valign='middle' align='center'>101 (0.9)</td><td colspan='1' rowspan='1' valign='middle' align='center'>2872 (3.1)</td><td colspan='1' rowspan='1' valign='middle' align='center'>14 088 (2.0)</td><td colspan='1' rowspan='1' valign='middle' align='center'>96 (0.8)</td><td colspan='1' rowspan='1' valign='middle' align='center'>2729 (3.0)</td><td colspan='1' rowspan='1' valign='middle' align='center'>13 395 (1.9)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Hispanic, black</td><td colspan='1' rowspan='1' valign='middle' align='center'>6 (0.05)</td><td colspan='1' rowspan='1' valign='middle' align='center'>209 (0.22)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1168 (0.16)</td><td colspan='1' rowspan='1' valign='middle' align='center'>6 (0.05)</td><td colspan='1' rowspan='1' valign='middle' align='center'>200 (0.22)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1132 (0.16)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Native American Indian</td><td colspan='1' rowspan='1' valign='middle' align='center'>8 (0.07)</td><td colspan='1' rowspan='1' valign='middle' align='center'>88 (0.09)</td><td colspan='1' rowspan='1' valign='middle' align='center'>653 (0.09)</td><td colspan='1' rowspan='1' valign='middle' align='center'>8 (0.07)</td><td colspan='1' rowspan='1' valign='middle' align='center'>85 (0.09)</td><td colspan='1' rowspan='1' valign='middle' align='center'>638 (0.09)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Black</td><td colspan='1' rowspan='1' valign='middle' align='center'>232 (2.0)</td><td colspan='1' rowspan='1' valign='middle' align='center'>2398 (2.6)</td><td colspan='1' rowspan='1' valign='middle' align='center'>31 374 (4.4)</td><td colspan='1' rowspan='1' valign='middle' align='center'>222 (1.9)</td><td colspan='1' rowspan='1' valign='middle' align='center'>2240 (2.5)</td><td colspan='1' rowspan='1' valign='middle' align='center'>29 816 (4.3)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Asian</td><td colspan='1' rowspan='1' valign='middle' align='center'>35 (0.3)</td><td colspan='1' rowspan='1' valign='middle' align='center'>210 (0.2)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1285 (0.2)</td><td colspan='1' rowspan='1' valign='middle' align='center'>35 (0.3)</td><td colspan='1' rowspan='1' valign='middle' align='center'>200 (0.2)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1222 (0.2)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> White</td><td colspan='1' rowspan='1' valign='middle' align='center'>3157 (27)</td><td colspan='1' rowspan='1' valign='middle' align='center'>28 976 (31)</td><td colspan='1' rowspan='1' valign='middle' align='center'>256 442 (36)</td><td colspan='1' rowspan='1' valign='middle' align='center'>3087 (27)</td><td colspan='1' rowspan='1' valign='middle' align='center'>28 082 (31)</td><td colspan='1' rowspan='1' valign='middle' align='center'>248 607 (36)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Unknown</td><td colspan='1' rowspan='1' valign='middle' align='center'>8164 (70)</td><td colspan='1' rowspan='1' valign='middle' align='center'>58 731 (63)</td><td colspan='1' rowspan='1' valign='middle' align='center'>409 294 (57)</td><td colspan='1' rowspan='1' valign='middle' align='center'>8053 (70)</td><td colspan='1' rowspan='1' valign='middle' align='center'>57 628 (63)</td><td colspan='1' rowspan='1' valign='middle' align='center'>401 588 (58)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'>Men</td><td colspan='1' rowspan='1' valign='middle' align='center'>11 392 (97)</td><td colspan='1' rowspan='1' valign='middle' align='center'>91 881 (98)</td><td colspan='1' rowspan='1' valign='middle' align='center'>701 201 (98)</td><td colspan='1' rowspan='1' valign='middle' align='center'>11 205 (97)</td><td colspan='1' rowspan='1' valign='middle' align='center'>89 641 (98)</td><td colspan='1' rowspan='1' valign='middle' align='center'>683 690 (98)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'>Women</td><td colspan='1' rowspan='1' valign='middle' align='center'>311 (3)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1603 (2)</td><td colspan='1' rowspan='1' valign='middle' align='center'>13 103 (2)</td><td colspan='1' rowspan='1' valign='middle' align='center'>302 (3)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1523 (2)</td><td colspan='1' rowspan='1' valign='middle' align='center'>12 708 (2)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'>Diseases:</td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Hypertension</td><td colspan='1' rowspan='1' valign='middle' align='center'>10 857 (93)</td><td colspan='1' rowspan='1' valign='middle' align='center'>85 441 (91)</td><td colspan='1' rowspan='1' valign='middle' align='center'>571 673 (80)</td><td colspan='1' rowspan='1' valign='middle' align='center'>10 676 (93)</td><td colspan='1' rowspan='1' valign='middle' align='center'>83 324 (91)</td><td colspan='1' rowspan='1' valign='middle' align='center'>557 617 (80)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Cardiovascular disease</td><td colspan='1' rowspan='1' valign='middle' align='center'>3967 (34)</td><td colspan='1' rowspan='1' valign='middle' align='center'>28 087 (30)</td><td colspan='1' rowspan='1' valign='middle' align='center'>357 331 (50)</td><td colspan='1' rowspan='1' valign='middle' align='center'>3886 (34)</td><td colspan='1' rowspan='1' valign='middle' align='center'>27 218 (30)</td><td colspan='1' rowspan='1' valign='middle' align='center'>347 973 (50)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Diabetes</td><td colspan='1' rowspan='1' valign='middle' align='center'>4090 (35)</td><td colspan='1' rowspan='1' valign='middle' align='center'>38 731 (41)</td><td colspan='1' rowspan='1' valign='middle' align='center'>151 945 (21)</td><td colspan='1' rowspan='1' valign='middle' align='center'>4020 (35)</td><td colspan='1' rowspan='1' valign='middle' align='center'>37 784 (41)</td><td colspan='1' rowspan='1' valign='middle' align='center'>147 687 (21)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Stroke</td><td colspan='1' rowspan='1' valign='middle' align='center'>1449 (12)</td><td colspan='1' rowspan='1' valign='middle' align='center'>12 776 (14)</td><td colspan='1' rowspan='1' valign='middle' align='center'>114 183 (16)</td><td colspan='1' rowspan='1' valign='middle' align='center'>1390 (12)</td><td colspan='1' rowspan='1' valign='middle' align='center'>11 933 (13)</td><td colspan='1' rowspan='1' valign='middle' align='center'>107 554 (15)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'>Blood pressure*:</td><td colspan='1' rowspan='1' valign='middle' align='center'>n=1078</td><td colspan='1' rowspan='1' valign='middle' align='center'>n=5439</td><td colspan='1' rowspan='1' valign='middle' align='center'>n=45 978</td><td colspan='1' rowspan='1' valign='middle' align='center'>n=988</td><td colspan='1' rowspan='1' valign='middle' align='center'>n=5012</td><td colspan='1' rowspan='1' valign='middle' align='center'>n=42 843</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Mean (SD) systolic blood pressure</td><td colspan='1' rowspan='1' valign='middle' align='center'>136 (13)</td><td colspan='1' rowspan='1' valign='middle' align='center'>134 (13)</td><td colspan='1' rowspan='1' valign='middle' align='center'>133 (14)</td><td colspan='1' rowspan='1' valign='middle' align='center'>136 (13)</td><td colspan='1' rowspan='1' valign='middle' align='center'>134 (13)</td><td colspan='1' rowspan='1' valign='middle' align='center'>133 (14)</td></tr><tr><td colspan='1' rowspan='1' valign='middle' align='left'> Mean (SD) diastolic blood pressure</td><td colspan='1' rowspan='1' valign='middle' align='center'>74 (8)</td><td colspan='1' rowspan='1' valign='middle' align='center'>73 (8)</td><td colspan='1' rowspan='1' valign='middle' align='center'>71 (8)</td><td colspan='1' rowspan='1' valign='middle' align='center'>74 (8)</td><td colspan='1' rowspan='1' valign='middle' align='center'>73 (8)</td><td colspan='1' rowspan='1' valign='middle' align='center'>72 (8)</td></tr></tbody></table><table-wrap-foot><p>*Subsample of patients from Veteran Affairs Vertically Integrated Service Network 1.</p></table-wrap-foot></table-wrap><sec><title>Incident Alzheimer’s disease and dementia</title><p><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Figure 1<xref rid='fig1' ref-type='fig'></xref> shows the survival curves for incident Alzheimer’s disease and dementia among participants in the three groups (see web extra table 1 for the unadjusted incident rates).</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Angiotensin receptor blockers were associated with significant reductions in incident Alzheimer’s disease compared with lisinopril (hazard rate 0.81, 95% confidence interval 0.68 to 0.96, P=0.016; table 2<xref rid='tbl2' ref-type='table'></xref>) or the cardiovascular comparator (0.84, 0.71 to 1.00, P=0.045; table 2).</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> More participants developed incident dementia than incident Alzheimer’s disease, although the results were similar to those for Alzheimer’s disease.</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Angiotensin receptor blockers were also associated with significant reductions in incident dementia compared with lisinopril (0.81, 0.73 to 0.90, P&lt;0.001) or the cardiovascular comparator (0.76, 0.69 to 0.84, P&lt;0.001; table 2).</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Adding hypertension and renal insufficiency as covariates did not change the outcomes (data not shown).</s></p><fig id='fig1' position='float'><caption><p><bold>Fig 1</bold> Survival function for incident Alzheimer’s disease and incident dementia in study cohorts</p></caption><graphic xlink:href='chen684415.f1_default'></graphic></fig><table-wrap id='tbl2' position='float'><label>Table 2</label><caption><p> Cox proportional hazard model for association between angiotensin receptor blockers and incidence of Alzheimer’s disease or dementia</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='2' valign='bottom' align='left'>Variables</th><th colspan='3' rowspan='1' valign='bottom' align='center'>Incidence of Alzheimer’s disease</th><th colspan='1' rowspan='1' valign='top' align='center'></th><th colspan='3' rowspan='1' valign='top' align='center'>Incidence of dementia</th></tr><tr><th colspan='1' rowspan='1' valign='bottom' align='center'>Estimate (SE)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>P value</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Hazard rate (95% CI)</th><th colspan='1' rowspan='1' valign='bottom' align='center'></th><th colspan='1' rowspan='1' valign='bottom' align='center'>Estimate (SE)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>P value</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Hazard rate* (95% CI)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Angiotensin receptor blocker <italic>v</italic> lisinopril</td><td colspan='1' rowspan='1' valign='bottom' align='center'>−0.213 (0.089)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.016</td><td colspan='1' rowspan='1' valign='bottom' align='left'>0.81 (0.68 to 0.96)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>−0.207 (0.053)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.81 (0.73 to 0.90)</td></tr><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Angiotensin receptor blocker <italic>v</italic> cardiovascular comparator</td><td colspan='1' rowspan='1' valign='bottom' align='center'>−0.171 (0.085)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.045</td><td colspan='1' rowspan='1' valign='bottom' align='left'>0.84 (0.71 to 1.00)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>−0.269 (0.051)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.76 (0.69 to 0.84)</td></tr><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Lisinopril <italic>v</italic> cardiovascular comparator</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.043 (0.029)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.145</td><td colspan='1' rowspan='1' valign='bottom' align='left'>1.04 (0.99 to 1.11)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>−0.061 (0.017)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.0004</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.94 (0.91 to 0.97)</td></tr><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Age</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.101 (0.001)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='left'>1.11 (1.10 to 1.11)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.087 (0.001)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='center'>1.09 (1.09 to 1.09)</td></tr><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Cardiovascular disease</td><td colspan='1' rowspan='1' valign='bottom' align='center'>−0.011 (0.017)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.505</td><td colspan='1' rowspan='1' valign='bottom' align='left'>0.99 (0.96 to 1.02)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.062 (0.010)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='center'>1.06 (1.04 to 1.09)</td></tr><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Diabetes</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.039 (0.020)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.049</td><td colspan='1' rowspan='1' valign='bottom' align='left'>1.04 (1.00 to 1.08)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.158 (0.011)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='center'>1.17 (1.15 to 1.20)</td></tr><tr><td colspan='1' rowspan='1' valign='bottom' align='left'>Stroke</td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.694 (0.018)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='left'>2.00 (1.93 to 2.07)</td><td colspan='1' rowspan='1' valign='bottom' align='center'></td><td colspan='1' rowspan='1' valign='bottom' align='center'>0.940 (0.010)</td><td colspan='1' rowspan='1' valign='bottom' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='bottom' align='center'>2.56 (2.51 to 2.61)</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for age, stroke, cardiovascular disease, and diabetes.</p></table-wrap-foot></table-wrap></sec><sec><title>Admission to nursing homes and death</title><p><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Web table 2 shows the unadjusted rates for admission to nursing homes of people with Alzheimer’s disease and death among patients with a diagnosis of Alzheimer’s disease and dementia.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> From the Cox proportional hazards models users of angiotensin receptor blockers with Alzheimer’s disease showed significantly lower rates of admissions to nursing homes (0.51, 0.36 to 0.72, P=0.0001) and death (0.83, 0.71 to 0.97, P=0.022) compared with users of the cardiovascular comparator drugs (table 3).</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Similar results were observed for patients with dementia (table 3<xref rid='tbl3' ref-type='table'></xref>).</s></p><table-wrap id='tbl3' position='float'><caption><p><bold>Table 3</bold> Cox proportional hazard model for association between angiotensin receptor blockers and disease progression (admission to nursing home or death) among participants with Alzheimer’s disease or dementia</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='2' valign='bottom' align='left'>Comparison groups</th><th colspan='3' rowspan='1' valign='bottom' align='center'>Admission to nursing home</th><th colspan='3' rowspan='1' valign='bottom' align='center'>Death</th></tr><tr><th colspan='1' rowspan='1' valign='bottom' align='center'>Estimate (SE)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>P value</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Hazard rate (95% CI)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Estimate (SE)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>P value</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Hazard rate* (95% CI)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' valign='top' align='left'>Alzheimer’s disease:</td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin receptor blocker <italic>v</italic> lisinopril</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.458 (0.182)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.0119</td><td colspan='1' rowspan='1' valign='top' align='center'>0.63 (0.44 to 0.90)</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.163 (0.084)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.054</td><td colspan='1' rowspan='1' valign='top' align='center'>0.85 (0.72 to 1.00)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin receptor blocker <italic>v</italic> cardiovascular comparator</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.671 (0.177)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.0001</td><td colspan='1' rowspan='1' valign='top' align='center'>0.51 (0.36 to 0.72)</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.187 (0.081)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.022</td><td colspan='1' rowspan='1' valign='top' align='center'>0.83 (0.71 to 0.97)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Lisinopril <italic>v</italic> cardiovascular comparator</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.213 (0.062)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.0006</td><td colspan='1' rowspan='1' valign='top' align='center'>0.81 (0.72 to 0.91)</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.024 (0.033)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.463</td><td colspan='1' rowspan='1' valign='top' align='center'>0.98 (0.92 to 1.04)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Age</td><td colspan='1' rowspan='1' valign='top' align='center'>0.025 (0.005)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.03 (1.02 to 1.04)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.053 (0.003)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.05 (1.05 to 1.06)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Cardiovascular disease</td><td colspan='1' rowspan='1' valign='top' align='center'>0.235 (0.055)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.27 (1.14 to 1.41)</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.019 (0.028)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.493</td><td colspan='1' rowspan='1' valign='top' align='center'>0.98 (0.93 to 1.04)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Diabetes</td><td colspan='1' rowspan='1' valign='top' align='center'>0.347 (0.053)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.41 (1.28 to 1.57)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.096 (0.029)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.10 (1.04 to 1.17)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Stroke</td><td colspan='1' rowspan='1' valign='top' align='center'>0.556 (0.052)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.74 (1.57 to 1.93)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.016 (0.029)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.595</td><td colspan='1' rowspan='1' valign='top' align='center'>1.02 (0.96 to 1.08)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'>Dementia:</td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td><td colspan='1' rowspan='1' valign='top' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin receptor blocker <italic>v</italic> lisinopril</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.308 (0.084)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.0002</td><td colspan='1' rowspan='1' valign='top' align='center'>0.74 (0.62 to 0.87)</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.139 (0.044)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>0.87 (0.80 to 0.95)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin receptor blocker <italic>v</italic> cardiovascular comparator</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.491 (0.081)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>0.61 (0.52 to 0.72)</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.120 (0.042)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.004</td><td colspan='1' rowspan='1' valign='top' align='center'>0.89 (0.82 to 0.96)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Lisinopril <italic>v</italic> cardiovascular comparator</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.184 (0.032)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>0.83 (0.78 to 0.89)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.019 (0.018)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.279</td><td colspan='1' rowspan='1' valign='top' align='center'>1.02 (0.99 to 1.06)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Age</td><td colspan='1' rowspan='1' valign='top' align='center'>0.027 (0.002)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.03 (1.02 to 1.03)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.056 (0.001)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.06 (1.06 to 1.06)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Cardiovascular disease</td><td colspan='1' rowspan='1' valign='top' align='center'>0.326 (0.031)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.39 (1.30 to 1.47)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.026 (0.016)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.112</td><td colspan='1' rowspan='1' valign='top' align='center'>1.03 (0.99 to 1.06)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Diabetes</td><td colspan='1' rowspan='1' valign='top' align='center'>0.282 (0.028)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.33 (1.26 to 1.40)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.078 (0.016)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.08 (1.05 to 1.12)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Stroke</td><td colspan='1' rowspan='1' valign='top' align='center'>0.588 (0.028)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.80 (1.71 to 1.90)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.065 (0.015)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>1.07 (1.04 to 1.10)</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for age, stroke, cardiovascular disease, and diabetes.</p></table-wrap-foot></table-wrap><p><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Stroke was the strongest factor associated with disease incidence or admission to a nursing home but a weaker factor in relation to death (tables 2 and 3).</s></p></sec><sec><title>Graded drug effects</title><p><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Sufficient numbers of participants used candesartan, irbesartan, losartan, or valsartan to study dose-response effects (see web extra table 4).</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Each drug showed a clear dose-response relation, with higher doses associated with lower rates of incident dementia (table 4<xref rid='tbl4' ref-type='table'></xref>).</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> For example, among participants in the high dose candesartan group the hazard rate for incident dementia was 27% lower than that in the low dose group.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> During the study the use of valsartan (and losartan) increased (see web extra fig 1).</s></p><table-wrap id='tbl4' position='float'><label>Table 4</label><caption><p> Effect of angiotensin receptor blocker dosage (high <italic>v</italic> low) on incidence of dementia</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='1' valign='top' align='left'>Angiotensin receptor blocker</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Estimate (SE)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>P value</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Hazard rate* (95% CI)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' valign='top' align='left'>Candesartan</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.322 (0.076)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>0.73 (0.62 to 0.84)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'>Irbesartan</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.174 (0.044)</td><td colspan='1' rowspan='1' valign='top' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='top' align='center'>0.84 (0.77 to 0.92)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'>Losartan</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.200 (0.066)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.0025</td><td colspan='1' rowspan='1' valign='top' align='center'>0.82 (0.72 to 0.93)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'>Valsartan</td><td colspan='1' rowspan='1' valign='top' align='center'>−0.103 (0.198)</td><td colspan='1' rowspan='1' valign='top' align='center'>0.602</td><td colspan='1' rowspan='1' valign='top' align='center'>0.91 (0.61 to 1.33)</td></tr></tbody></table><table-wrap-foot><p>*Cox proportional hazard model adjusted for age, cardiovascular disease, diabetes, and stroke.</p></table-wrap-foot></table-wrap><p><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>A multidrug use model was used to examine whether participants who switched from angiotensin converting enzyme inhibitors to angiotensin receptor blockers, or the converse, adopted the dementia hazard rate for the subsequent drug.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Participants were not excluded for using more than one drug type during the study.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Participants were those without a previous diagnosis of dementia who were prescribed angiotensin receptor blockers or angiotensin converting enzyme inhibitors (but not both) and showed stable use of the drug over the first six months after entry into the study on the basis of a drug possession ratio of 80% or greater.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> All relevant drugs included in the Veteran Affairs health system formulary were used by the angiotensin converting enzyme inhibitors group.</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Participants who used angiotensin receptor blockers throughout the study or who started using angiotensin converting enzyme inhibitors and switched to angiotensin receptor blockers showed a significantly lower odds of incident dementia than the reference group that did not switch from angiotensin converting enzyme inhibitors throughout the study (0.28, 0.24 to 0.32, P&lt;0.001; table 5<xref rid='tbl5' ref-type='table'></xref>).</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, participants who initially received angiotensin receptor blockers but then switched to angiotensin converting enzyme inhibitors showed a non-significantly different risk of incident dementia than the reference group (table 5).</s></p><table-wrap id='tbl5' position='float'><label>Table 5</label><caption><p> Effects of switching drug class on incidence of dementia</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='1' valign='middle' align='left'>Variables</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Estimate (SE)</th><th colspan='1' rowspan='1' valign='bottom' align='center'>P value</th><th colspan='1' rowspan='1' valign='bottom' align='center'>Hazard rate* (95% CI)</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' valign='top' align='left'>Variables:</td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin receptor blocker to angiotensin receptor blocker†</td><td colspan='1' rowspan='1' valign='middle' align='center'>−0.73 (0.018)</td><td colspan='1' rowspan='1' valign='middle' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.48 (0.47 to 0.50)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin receptor blocker to angiotensin converting enzyme inhibitor‡</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.16 (0.169)</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.3562</td><td colspan='1' rowspan='1' valign='middle' align='center'>1.17 (0.84 to 1.63)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Angiotensin converting enzyme inhibitor to angiotensin receptor blocker§</td><td colspan='1' rowspan='1' valign='middle' align='center'>−1.28 (0.073)</td><td colspan='1' rowspan='1' valign='middle' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.28 (0.24 to 0.32)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'>Covariables:</td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td><td colspan='1' rowspan='1' valign='middle' align='center'></td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Age</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.09 (0.001)</td><td colspan='1' rowspan='1' valign='middle' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='middle' align='center'>1.10 (1.09 to 1.10)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Cardiovascular disease</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.12 (0.017)</td><td colspan='1' rowspan='1' valign='middle' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='middle' align='center'>1.13 (1.09 to 1.17)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Diabetes</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.28 (0.016)</td><td colspan='1' rowspan='1' valign='middle' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='middle' align='center'>1.33 (1.29 to 1.37)</td></tr><tr><td colspan='1' rowspan='1' valign='top' align='left'> Stroke</td><td colspan='1' rowspan='1' valign='middle' align='center'>0.96 (0.016)</td><td colspan='1' rowspan='1' valign='middle' align='center'>&lt;0.001</td><td colspan='1' rowspan='1' valign='middle' align='center'>2.61 (2.53 to 2.69)</td></tr></tbody></table><table-wrap-foot><p>Reference group: angiotensin converting enzyme inhibitor to angiotensin converting enzyme inhibitor.</p><p>*Cox proportional hazard model adjusted for age, stroke, diabetes, and cardiovascular disease.</p><p>†Participants used angiotensin receptor blocker throughout study.</p><p>‡Participants switched from angiotensin receptor blocker to angiotensin converting enzyme inhibitor by end of study.</p><p>§Participants switched from angiotensin converting enzyme inhibitor to angiotensin receptor blocker by end of study.</p></table-wrap-foot></table-wrap></sec><sec><title>Additive effects</title><p><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1>As angiotensin receptor blockers and angiotensin converting enzyme inhibitors both decrease signalling through the AT1 receptor, we hypothesised that their combined use might result in added inhibition, leading to enhanced clinical efficacy.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> We examined the effects of combined use on incident Alzheimer’s disease or dementia among participants without a previous diagnosis of dementia, and on nursing home admissions among participants with pre-existing Alzheimer’s disease or dementia.</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Combined use was generally associated with lower outcome rates than use of angiotensin receptor blockers alone, angiotensin converting enzyme inhibitor alone, or lisinopril alone (fig 2<xref rid='fig2' ref-type='fig'></xref> and web extra table 5).</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> For example, the hazard rate for the drug combination compared with angiotensin converting enzyme inhibitors alone for incident Alzheimer’s disease was 0.45 (0.41 to 0.50, P&lt;0.001) and for dementia was 0.54 (0.51 to 0.57, P&lt;0.001, fig 2 and web extra table 5).</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The hazard rate for admission to a nursing home among patients with dementia was 0.33 (0.22 to 0.49, P&lt;0.001) for combined use of angiotensin receptor blockers and angiotensin converting enzymes compared with lisinopril or any angiotensin converting enzyme inhibitor alone (fig 2 and web extra table 5).</s></p><fig id='fig2' position='float'><caption><p><bold>Fig 2</bold> Additive effects of angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors compared with single drug use. Hazard rates (95% confidence intervals) are adjusted for age, stroke, diabetes, and cardiovascular disease</p></caption><graphic xlink:href='chen684415.f2_default'></graphic></fig></sec></sec><sec sec-type='discussion'><title>Discussion</title><p><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>This study suggests that angiotensin receptor blockers are associated with reduced incidence and progression of Alzheimer’s disease and dementia compared with other drugs for cardiovascular disease or hypertension.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> One of the measures used for disease progression was admission to a nursing home.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> The robust reduction in such admissions associated with use of angiotensin receptor blockers is a particularly important observation that could have a major impact on public health if validated by future studies.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> The strength and consistency of the effect over several different analyses supports the validity of this finding.</s></p><p><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Use of angiotensin receptor blockers was associated with a significant dose-response profile for incident dementia, with the brain penetrant angiotensin receptor blocker candesartan showing the strongest dose dependent reduction in incident dementia.</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Lisinopril, one of the main comparators, is not a brain penetrant, although whether brain penetration increases with dementia is unknown.<xref rid='ref41' ref-type='bibr'>41</xref></s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, when we compared the effects of angiotensin receptor blockers with that of the entire group of angiotensin converting enzyme inhibitors (see table 4), switching from angiotensin converting enzyme inhibitors to angiotensin receptor blockers was also associated with reductions in dementia.</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This suggests that selection bias linked to initial assignment of treatment with either drug class does not determine the outcome.</s><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Finally, both drug classes showed additive benefits, which is consistent with their mutual activity at the AT1 receptor.</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Additive effects were observed for lisinopril alone and for angiotensin converting enzyme inhibitors generally (fig 2 and web extra table 5).</s><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The additive benefits of both drug classes is consistent with recent prospective clinical trials.<xref rid='ref24' ref-type='bibr'>24</xref></s><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Combination therapy therefore could be particularly beneficial for patients.</s></p><p><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>For the study of incident Alzheimer’s disease and dementia, we examined drugs using a “single drug” model that restricted drug classes to one particular group on entry and for the duration of the study.</s><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The other studies had fewer participants, which required use of a polypharmacy model to obtain sufficient power.</s><s sid='145'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In the polypharmacy model, use of lisinopril or angiotensin converting enzyme inhibitors was disallowed for participants in the angiotensin receptor blocker cohort entering the study; however, addition of either was allowed any time beyond six months after study entry.</s><s sid='146'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The rationale for the polypharmacy approach is that angiotensin receptor blockers might show a “gain of protection” compared with angiotensin converting enzyme inhibitors.</s><s sid='147'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The effects associated with additive drug use and with switching between the two drug classes (see tables 4 and 5) indicate that angiotensin receptor blockers are associated with better outcomes than use of angiotensin converting enzyme inhibitors, as shown by the greater effect observed with a higher dose and with combined use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors.</s></p><sec><title>Strengths and limitations of the study</title><p><s sid='148'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>An important strength of our study was the use of comparators from the same class of drugs, which allowed cohorts that share similar demographic, health status, and hospital utilisation profiles to be compared.</s><s sid='149'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Our study covered a five year period.</s><s sid='150'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A longer time frame, however, might be associated with a more robust outcome because studies show that cardiovascular risk factors exert their impact on dementia beginning in mid-life.<xref rid='ref42' ref-type='bibr'>42</xref><xref rid='ref43' ref-type='bibr'>43</xref><xref rid='ref44' ref-type='bibr'>44</xref><xref rid='ref45' ref-type='bibr'>45</xref></s></p><p><s sid='151'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Misclassification, such as misdiagnosis or missing information, is an important factor that could bias the data.</s><s sid='152'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We compared rates of participants lost to follow-up in each cohort but observed no significant differences.</s><s sid='153'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also included Alzheimer’s disease and dementia as independent outcomes to control for problems with diagnostic sensitivity or specificity associated with population derived databases.</s><s sid='154'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition, misclassification would seem to bias towards the null hypothesis.</s><s sid='155'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Studies of population databases are prone to other unanticipated biases.</s><s sid='156'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Comorbidities might differ among the cohorts.</s><s sid='157'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Indeed, diabetes and stroke were significantly associated with some of the outcomes.</s><s sid='158'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, such conditions are associated with higher rates of Alzheimer’s disease and dementia, which would tend to decrease the size of any association of angiotensin receptor blockers with reduced rates of these diseases.</s><s sid='159'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Although we compared mean blood pressure between the groups (no differences were observed), we did not determine mean blood pressure lowering for angiotensin receptor blockers and angiotensin converting enzyme inhibitors.</s><s sid='160'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Studies have suggested that these drug classes achieve similar levels of blood pressure lowering, differences between the groups could contribute to the putative benefit towards dementia associated with angiotensin receptor blocker use.<xref rid='ref13' ref-type='bibr'>13</xref></s><s sid='161'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Multiple indication bias could dilute the effects of our findings but this would bias towards the null hypothesis.</s><s sid='162'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Under-diagnosis exists in the decision support system database, but our three cohorts had similar rates of hospital utilisation.</s></p><p><s sid='163'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The open nature of the medical system in the United States also raises the possibility of a bias among participants using the Veterans Affairs healthcare system.</s><s sid='164'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> One study showed high rates of use of the Veterans Affairs healthcare system by patients for primary health care and primary pharmacy sources.<xref rid='ref46' ref-type='bibr'>46</xref></s><s sid='165'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Our study incorporated losses to follow-up as an exclusion criterion, but omission of this from the model yielded similar outcomes, suggesting that only minor differences existed for source of healthcare use among the cohorts.</s><s sid='166'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Additional bias could come from several sources.</s><s sid='167'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Admission to a nursing home depends on factors that are independent of dementia, such as the ability of care givers to care for patients.</s><s sid='168'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Bias can also come from nursing home use, as participants can vary in their choice of nursing homes affiliated with the Veterans Affairs system or private systems.</s><s sid='169'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> About half of the participants in the Veterans Affairs system choose nursing homes affiliated with the Veterans Affairs.<xref rid='ref47' ref-type='bibr'>47</xref></s><s sid='170'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Analysis of nursing home admissions on the basis of nursing homes affiliated with the Veterans Affairs system might introduce a general selection bias in our cohorts, but such bias needs to be assessed in the context of similar rates of losses to follow-up and use of cohorts based on similar drug classes that are also similar by other measures examined.</s><s sid='171'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Characterisation of bias in choice of nursing homes requires harmonisation of the Veterans Affairs and Medicare databases, which has not yet been achieved.</s><s sid='172'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Other unanticipated biases might also exist due to unmeasured variables, such as instrumental variables (for example, income, exercise).</s><s sid='173'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> None the less, pharmacoepidemiological studies of drugs on risk of dementia need to be evaluated in large populations that permit adequate statistical power to control for confounding by indication.</s><s sid='174'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The present study is the first to compare both risk of dementia and progression of dementia in users of angiotensin receptor blockers compared with users of a drug from the same class (lisinopril) or users of other drugs prescribed for cardiovascular disease.</s></p></sec><sec><title>Biological mechanisms</title><p><s sid='175'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Stroke was consistently ranked as the most important covariate in our dataset.</s><s sid='176'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The strong association of stroke with dementia and nursing home admission in our study is consistent with previous studies, suggesting the importance of vascular factors in progression of cognitive loss.<xref rid='ref48' ref-type='bibr'>48</xref><xref rid='ref49' ref-type='bibr'>49</xref><xref rid='ref50' ref-type='bibr'>50</xref></s><s sid='177'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Decreased cerebral blood flow is a common and early observation among people with Alzheimer’s disease.<xref rid='ref49' ref-type='bibr'>49</xref></s><s sid='178'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous studies suggest that angiotensin receptor blockers offer an important advantage over angiotensin converting enzyme inhibitors and other antihypertensive agents in improving outcomes from stroke.<xref rid='ref7' ref-type='bibr'>7</xref><xref rid='ref51' ref-type='bibr'>51</xref><xref rid='ref52' ref-type='bibr'>52</xref><xref rid='ref53' ref-type='bibr'>53</xref></s><s sid='179'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recent results from the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), which examined the effects of telmisartan plus ramipril, observed a decrease in secondary stroke associated with use of telmisartan, but the lowering of stroke rates did not reach significance.<xref rid='ref54' ref-type='bibr'>54</xref></s><s sid='180'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Animal studies report that angiotensin receptor blockers elicit neuroprotective responses that are independent of decreases in blood pressure and are apparent even in cell culture.<xref rid='ref18' ref-type='bibr'>18</xref><xref rid='ref52' ref-type='bibr'>52</xref></s><s sid='181'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Vascular dysfunction induced by amyloid β, the protein that accumulates in Alzheimer’s disease, plays an important part in the disease.</s><s sid='182'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Loss of cerebral blood flow is a prominent and early feature of the disease, perhaps as a result of the accumulation of amyloid β.<xref rid='ref49' ref-type='bibr'>49</xref><xref rid='ref55' ref-type='bibr'>55</xref><xref rid='ref56' ref-type='bibr'>56</xref></s><s sid='183'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Angiotensin receptor blockers seem to be particularly effective at preventing vascular damage induced by amyloid β.<xref rid='ref57' ref-type='bibr'>57</xref><xref rid='ref58' ref-type='bibr'>58</xref><xref rid='ref59' ref-type='bibr'>59</xref></s><s sid='184'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Because vascular dysfunction and stroke are associated with cognitive decline, our data raise the possibility that combined use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors might confer superior protection against cognitive decline (compared with other cardiovascular drugs) by reducing neuronal damage associated with stroke and vascular dysfunction.</s></p><p><s sid='185'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Diabetes is a strong risk factor for Alzheimer’s disease and dementia, and diabetes was a significant covariate in our study.<xref rid='ref3' ref-type='bibr'>3</xref><xref rid='ref60' ref-type='bibr'>60</xref><xref rid='ref61' ref-type='bibr'>61</xref></s><s sid='186'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Clinical studies also indicate that angiotensin receptor blockers offer superior protection against diabetes compared with other antihypertensive drugs.<xref rid='ref13' ref-type='bibr'>13</xref><xref rid='ref23' ref-type='bibr'>23</xref></s><s sid='187'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Angiotensin receptor blocker mediated protection against deleterious effects of diabetes might also contribute to the positive results observed in this study.</s><s sid='188'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The biochemical mechanisms contributing to the putative beneficial clinical outcomes resulting from modulation of the renin-angiotensin system are difficult to identify and could be pleiotropic.</s><s sid='189'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Potential mechanisms are reviewed elsewhere.<xref rid='ref32' ref-type='bibr'>32</xref><xref rid='ref33' ref-type='bibr'>33</xref></s><s sid='190'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Regardless of the mechanism, our study suggests that selective blockade of the angiotensin II receptor AT1 offers important health benefits to those with cognitive decline, and combined use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors is associated with even greater benefits.</s></p><boxed-text content-type='style3' position='float'><sec><title>What is already known on this topic</title><list list-type='simple'><list-item><p>Studies suggest that angiotensin receptor blockers offer superior protection against diabetes and possibly stroke compared with other antihypertensives</p></list-item></list></sec><sec><title>What this study adds</title><list list-type='simple'><list-item><p>Angiotensin receptor blockers are associated with a reduced incidence of Alzheimer’s disease and dementia</p></list-item><list-item><p>They are also associated with reduced rates of disease progression (admission to nursing homes and death) among people with Alzheimer’s disease and dementia</p></list-item><list-item><p>Angiotensin receptor blockers seem to offer superior protection against Alzheimer’s disease and dementia compared with other antihypertensives and cardiovascular drugs</p></list-item></list></sec></boxed-text></sec></sec></body><back><notes><fn-group><fn fn-type='participating-researchers'><p>Contributors: N-CL acquired and analysed the data, critically revised the manuscript, and provided technical support. AL and EL designed the study, acquired the data, did the statistical analysis, and critically revised the manuscript. RAW and MK interpreted the data and critically revised the manuscript for important intellectual content. LEK designed the study, analysed and interpreted the data, obtained funding, and critically revised the manuscript. BW conceived, designed, and supervised the study, analysed and interpreted the data, drafted the manuscript, and obtained funding. He is guarantor.</p></fn><fn fn-type='financial-disclosure'><p>Funding: This work was supported by a grant award to BW from the Retirement Research Foundation and a donation from the Casten Foundation. The researchers operate independently of the funders of the study.</p></fn><fn fn-type='conflict'><p>Competing interests: BW and RAW received a grant award from the Retirement Research Foundation to fund this research. BW received a donation from the Casten Foundation to fund this research. </p></fn><fn><p>Ethical approval: This study was approved by internal review boards of the Boston University School of Medicine, the Bedford Veterans Affairs Medical Center, and Jamaica Plains Veterans Affairs Medical Center. The study was based on administrative datasets and the participants were not identifiable to the authors.</p></fn><fn><p>Data sharing: No additional data available.</p></fn></fn-group></notes><ref-list><ref id='ref1'><label>1</label><mixed-citation publication-type='journal'>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. <source>Neurology</source><year>2005</year>;<volume>64</volume>:<fpage>277</fpage>-81.<pub-id pub-id-type='pmid'>15668425</pub-id></mixed-citation></ref><ref id='ref2'><label>2</label><mixed-citation publication-type='journal'>Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. <source>Am J Cardiol</source><year>2006</year>;<volume>97</volume>:<fpage>1262</fpage>-5.<pub-id pub-id-type='pmid'>16616038</pub-id></mixed-citation></ref><ref id='ref3'><label>3</label><mixed-citation publication-type='journal'>Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. <source>Neurology</source><year>2005</year>;<volume>65</volume>:<fpage>545</fpage>-51.<pub-id pub-id-type='pmid'>16116114</pub-id></mixed-citation></ref><ref id='ref4'><label>4</label><mixed-citation publication-type='journal'>Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et al. Dementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. <source>J Am Geriatr Soc</source><year>2005</year>;<volume>53</volume>:<fpage>1101</fpage>-7.<pub-id pub-id-type='pmid'>16108925</pub-id></mixed-citation></ref><ref id='ref5'><label>5</label><mixed-citation publication-type='journal'>Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. <source>BMJ</source><year>1994</year>;<volume>308</volume>:<fpage>1604</fpage>-8.<pub-id pub-id-type='pmid'>8025427</pub-id></mixed-citation></ref><ref id='ref6'><label>6</label><mixed-citation publication-type='journal'>Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. <source>Arch Neurol</source><year>2006</year>;<volume>63</volume>:<fpage>686</fpage>-92.<pub-id pub-id-type='pmid'>16533956</pub-id></mixed-citation></ref><ref id='ref7'><label>7</label><mixed-citation publication-type='journal'>Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). <source>Am J Hypertens</source><year>2005</year>;<volume>18</volume>:<fpage>1052</fpage>-9.<pub-id pub-id-type='pmid'>16109319</pub-id></mixed-citation></ref><ref id='ref8'><label>8</label><mixed-citation publication-type='journal'>Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. <source>Arch Intern Med</source><year>2002</year>;<volume>162</volume>:<fpage>2046</fpage>-52.<pub-id pub-id-type='pmid'>12374512</pub-id></mixed-citation></ref><ref id='ref9'><label>9</label><mixed-citation publication-type='journal'>Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. <source>Lancet Neurol</source><year>2005</year>;<volume>4</volume>:<fpage>487</fpage>-99.<pub-id pub-id-type='pmid'>16033691</pub-id></mixed-citation></ref><ref id='ref10'><label>10</label><mixed-citation publication-type='journal'>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. <source>Arch Neurol</source><year>2000</year>;<volume>57</volume>:<fpage>1439</fpage>-43.<pub-id pub-id-type='pmid'>11030795</pub-id></mixed-citation></ref><ref id='ref11'><label>11</label><mixed-citation publication-type='journal'>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. <source>Lancet</source><year>2000</year>;<volume>356</volume>:<fpage>1627</fpage>-31.<pub-id pub-id-type='pmid'>11089820</pub-id></mixed-citation></ref><ref id='ref12'><label>12</label><mixed-citation publication-type='journal'>Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. <source>N Engl J Med</source><year>2004</year>;<volume>351</volume>:<fpage>2058</fpage>-68.<pub-id pub-id-type='pmid'>15531767</pub-id></mixed-citation></ref><ref id='ref13'><label>13</label><mixed-citation publication-type='journal'>Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. <source>Ann Intern Med</source><year>2008</year>;<volume>148</volume>:<fpage>16</fpage>-29.<pub-id pub-id-type='pmid'>17984484</pub-id></mixed-citation></ref><ref id='ref14'><label>14</label><mixed-citation publication-type='journal'>Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. <source>Nat Rev Drug Discov</source><year>2002</year>;<volume>1</volume>:<fpage>621</fpage>-36.<pub-id pub-id-type='pmid'>12402502</pub-id></mixed-citation></ref><ref id='ref15'><label>15</label><mixed-citation publication-type='journal'>Gallinat S, Yu M, Dorst A, Unger T, Herdegen T. Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. <source>Brain Res Mol Brain Res</source><year>1998</year>;<volume>57</volume>:<fpage>111</fpage>-22.<pub-id pub-id-type='pmid'>9630555</pub-id></mixed-citation></ref><ref id='ref16'><label>16</label><mixed-citation publication-type='journal'>Inagami T, Kambayashi Y, Ichiki T, Tsuzuki S, Eguchi S, Yamakawa T. Angiotensin receptors: molecular biology and signalling. <source>Clin Exp Pharmacol Physiol</source><year>1999</year>;<volume>26</volume>:<fpage>544</fpage>-9.<pub-id pub-id-type='pmid'>10405785</pub-id></mixed-citation></ref><ref id='ref17'><label>17</label><mixed-citation publication-type='journal'>Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. <source>J Clin Invest</source><year>1995</year>;<volume>95</volume>:<fpage>651</fpage>-7.<pub-id pub-id-type='pmid'>7860748</pub-id></mixed-citation></ref><ref id='ref18'><label>18</label><mixed-citation publication-type='journal'>Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. <source>J Exp Med</source><year>1998</year>;<volume>188</volume>:<fpage>661</fpage>-70.<pub-id pub-id-type='pmid'>9705948</pub-id></mixed-citation></ref><ref id='ref19'><label>19</label><mixed-citation publication-type='journal'>Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. <source>Neurology</source><year>2004</year>;<volume>63</volume>:<fpage>1324</fpage>-5.<pub-id pub-id-type='pmid'>15477567</pub-id></mixed-citation></ref><ref id='ref20'><label>20</label><mixed-citation publication-type='journal'>Rozzini L, Chilovi BV, Bertoletti E, Conti M, Del Rio I, Trabucchi M, et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. <source>Int J Geriatr Psychiatry</source><year>2006</year>;<volume>21</volume>:<fpage>550</fpage>-5.<pub-id pub-id-type='pmid'>16642542</pub-id></mixed-citation></ref><ref id='ref21'><label>21</label><mixed-citation publication-type='journal'>Parhofer KG, Munzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. <source>Cardiovasc Diabetol</source><year>2007</year>;<volume>6</volume>:<fpage>36</fpage><pub-id pub-id-type='pmid'>18042288</pub-id></mixed-citation></ref><ref id='ref22'><label>22</label><mixed-citation publication-type='journal'>Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). <source>Am J Cardiol</source><year>2007</year>;<volume>99</volume>:<fpage>1006</fpage>-12.<pub-id pub-id-type='pmid'>17398202</pub-id></mixed-citation></ref><ref id='ref23'><label>23</label><mixed-citation publication-type='journal'>Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. <source>Lancet</source><year>2007</year>;<volume>369</volume>:<fpage>201</fpage>-7.<pub-id pub-id-type='pmid'>17240286</pub-id></mixed-citation></ref><ref id='ref24'><label>24</label><mixed-citation publication-type='journal'>Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. <source>J Card Fail</source><year>2005</year>;<volume>11</volume>:<fpage>253</fpage>-9.<pub-id pub-id-type='pmid'>15880333</pub-id></mixed-citation></ref><ref id='ref25'><label>25</label><mixed-citation publication-type='journal'>Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial. <source>Eur J Heart Fail</source><year>2008</year>;<volume>10</volume>:<fpage>157</fpage>-63.<pub-id pub-id-type='pmid'>18242128</pub-id></mixed-citation></ref><ref id='ref26'><label>26</label><mixed-citation publication-type='journal'>Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. <source>J Hypertens</source><year>2008</year>;<volume>26</volume>:<fpage>1642</fpage>-50.<pub-id pub-id-type='pmid'>18622244</pub-id></mixed-citation></ref><ref id='ref27'><label>27</label><mixed-citation publication-type='journal'>Raghavendra V, Chopra K, Kulkarni SK. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. <source>Neuropeptides</source><year>1998</year>;<volume>32</volume>:<fpage>417</fpage>-21.<pub-id pub-id-type='pmid'>9845001</pub-id></mixed-citation></ref><ref id='ref28'><label>28</label><mixed-citation publication-type='journal'>Raghavendra V, Chopra K, Kulkarni SK. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. <source>Neuropeptides</source><year>2001</year>;<volume>35</volume>:<fpage>65</fpage>-9.<pub-id pub-id-type='pmid'>11346312</pub-id></mixed-citation></ref><ref id='ref29'><label>29</label><mixed-citation publication-type='journal'>Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. <source>J Hum Hypertens</source><year>2003</year>;<volume>17</volume>:<fpage>781</fpage>-5.<pub-id pub-id-type='pmid'>14578918</pub-id></mixed-citation></ref><ref id='ref30'><label>30</label><mixed-citation publication-type='journal'>Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. <source>Am J Hypertens</source><year>1999</year>;<volume>12</volume>:<fpage>1130</fpage>-4.<pub-id pub-id-type='pmid'>10604491</pub-id></mixed-citation></ref><ref id='ref31'><label>31</label><mixed-citation publication-type='journal'>Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. <source>Pharmacotherapy</source><year>2008</year>;<volume>28</volume>:<fpage>366</fpage>-75.<pub-id pub-id-type='pmid'>18294116</pub-id></mixed-citation></ref><ref id='ref32'><label>32</label><mixed-citation publication-type='journal'>Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? <source>Lancet Neurol</source><year>2007</year>;<volume>6</volume>:<fpage>373</fpage>-8.<pub-id pub-id-type='pmid'>17362841</pub-id></mixed-citation></ref><ref id='ref33'><label>33</label><mixed-citation publication-type='journal'>Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer’s disease—friend or foe? <source>Trends Neurosci</source><year>2009</year>;<volume>32</volume>:<fpage>619</fpage>-28.<pub-id pub-id-type='pmid'>19796831</pub-id></mixed-citation></ref><ref id='ref34'><label>34</label><mixed-citation publication-type='journal'>Smith MW, Joseph GJ. Pharmacy data in the VA health care system. <source>Med Care Res Rev</source><year>2003</year>;<volume>60</volume>:<fpage>92</fpage>-123S.</mixed-citation></ref><ref id='ref35'><label>35</label><mixed-citation publication-type='journal'>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. <source>Ann Intern Med</source><year>1999</year>;<volume>130</volume>:<fpage>461</fpage>-70.<pub-id pub-id-type='pmid'>10075613</pub-id></mixed-citation></ref><ref id='ref36'><label>36</label><mixed-citation publication-type='journal'>Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer’s disease: prospective analyses from the Predictors Study. <source>Neurology</source><year>1994</year>;<volume>44</volume>:<fpage>2300</fpage>-7.<pub-id pub-id-type='pmid'>7991116</pub-id></mixed-citation></ref><ref id='ref37'><label>37</label><mixed-citation publication-type='journal'>Smith F, Talwalker S, Gracon S, Srirama M. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer’s disease. <source>J Biopharm Stat</source><year>1996</year>;<volume>6</volume>:<fpage>395</fpage>-409.<pub-id pub-id-type='pmid'>8969976</pub-id></mixed-citation></ref><ref id='ref38'><label>38</label><mixed-citation publication-type='journal'>Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. <source>JAMA</source><year>1997</year>;<volume>277</volume>:<fpage>806</fpage>-12.<pub-id pub-id-type='pmid'>9052710</pub-id></mixed-citation></ref><ref id='ref39'><label>39</label><mixed-citation publication-type='journal'>Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. <source>J Am Geriatr Soc</source><year>2003</year>;<volume>51</volume>:<fpage>937</fpage>-44.<pub-id pub-id-type='pmid'>12834513</pub-id></mixed-citation></ref><ref id='ref40'><label>40</label><mixed-citation publication-type='journal'>Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. <source>JAMA</source><year>2003</year>;<volume>289</volume>:<fpage>2819</fpage>-26.<pub-id pub-id-type='pmid'>12783912</pub-id></mixed-citation></ref><ref id='ref41'><label>41</label><mixed-citation publication-type='journal'>Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. <source>Pharm Res</source><year>1992</year>;<volume>9</volume>:<fpage>1480</fpage>-6.<pub-id pub-id-type='pmid'>1475237</pub-id></mixed-citation></ref><ref id='ref42'><label>42</label><mixed-citation publication-type='journal'>Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. <source>Neurobiol Aging</source><year>2000</year>;<volume>21</volume>:<fpage>49</fpage>-55.<pub-id pub-id-type='pmid'>10794848</pub-id></mixed-citation></ref><ref id='ref43'><label>43</label><mixed-citation publication-type='journal'>Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I. Cholesterol and Alzheimer’s disease—is there a relation? <source>Mech Ageing Dev</source><year>2006</year>;<volume>127</volume>:<fpage>138</fpage>-47.<pub-id pub-id-type='pmid'>16332384</pub-id></mixed-citation></ref><ref id='ref44'><label>44</label><mixed-citation publication-type='journal'>Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. <source>BMJ</source><year>2001</year>;<volume>322</volume>:<fpage>1447</fpage>-51.<pub-id pub-id-type='pmid'>11408299</pub-id></mixed-citation></ref><ref id='ref45'><label>45</label><mixed-citation publication-type='journal'>Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. <source>Lancet Neurol</source><year>2006</year>;<volume>5</volume>:<fpage>735</fpage>-41.<pub-id pub-id-type='pmid'>16914401</pub-id></mixed-citation></ref><ref id='ref46'><label>46</label><mixed-citation publication-type='journal'>Hamed A, Lee A, Ren XS, Miller DR, Cunningham F, Zhang H, et al. Use of antidepressant medications: are there differences in psychiatric visits among patient treatments in the Veterans Administration? <source>Med Care</source><year>2004</year>;<volume>42</volume>:<fpage>551</fpage>-9.<pub-id pub-id-type='pmid'>15167323</pub-id></mixed-citation></ref><ref id='ref47'><label>47</label><mixed-citation publication-type='journal'>Kinosian B, Stallard E, Wieland D. Projected use of long-term-care services by enrolled veterans. <source>Gerontologist</source><year>2007</year>;<volume>47</volume>:<fpage>356</fpage>-64.<pub-id pub-id-type='pmid'>17565100</pub-id></mixed-citation></ref><ref id='ref48'><label>48</label><mixed-citation publication-type='journal'>De la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. <source>Lancet Neurol</source><year>2004</year>;<volume>3</volume>:<fpage>184</fpage>-90.<pub-id pub-id-type='pmid'>14980533</pub-id></mixed-citation></ref><ref id='ref49'><label>49</label><mixed-citation publication-type='journal'>Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. <source>Ann Neurol</source><year>2005</year>;<volume>57</volume>:<fpage>789</fpage>-94.<pub-id pub-id-type='pmid'>15929050</pub-id></mixed-citation></ref><ref id='ref50'><label>50</label><mixed-citation publication-type='journal'>Encinas M, De Juan R, Marcos A, Gil P, Barabash A, Fernandez C, et al. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer’s disease. <source>Eur J Nucl Med Mol Imaging</source><year>2003</year>;<volume>30</volume>:<fpage>1473</fpage>-80.<pub-id pub-id-type='pmid'>14579086</pub-id></mixed-citation></ref><ref id='ref51'><label>51</label><mixed-citation publication-type='journal'>Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. <source>J Hypertens Suppl</source><year>2006</year>;<volume>24</volume>:<fpage>115</fpage>-21S.</mixed-citation></ref><ref id='ref52'><label>52</label><mixed-citation publication-type='journal'>Wilms H, Rosenstiel P, Unger T, Deuschl G, Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. <source>Am J Cardiovasc Drugs</source><year>2005</year>;<volume>5</volume>:<fpage>245</fpage>-53.<pub-id pub-id-type='pmid'>15984907</pub-id></mixed-citation></ref><ref id='ref53'><label>53</label><mixed-citation publication-type='journal'>Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. <source>J Hypertens</source><year>2008</year>;<volume>26</volume>:<fpage>544</fpage>-52.<pub-id pub-id-type='pmid'>18300867</pub-id></mixed-citation></ref><ref id='ref54'><label>54</label><mixed-citation publication-type='journal'>Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>1547</fpage>-59.<pub-id pub-id-type='pmid'>18378520</pub-id></mixed-citation></ref><ref id='ref55'><label>55</label><mixed-citation publication-type='journal'>Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO. Cerebral perfusion as a diagnostic marker of early Alzheimer’s disease. <source>Neurology</source><year>1988</year>;<volume>38</volume>:<fpage>931</fpage>-7.<pub-id pub-id-type='pmid'>3368076</pub-id></mixed-citation></ref><ref id='ref56'><label>56</label><mixed-citation publication-type='journal'>Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. A beta-peptides enhance vasoconstriction in cerebral circulation. <source>Am J Physiol Heart Circ Physiol</source><year>2001</year>;<volume>281</volume>:<fpage>H2417</fpage>-24.<pub-id pub-id-type='pmid'>11709407</pub-id></mixed-citation></ref><ref id='ref57'><label>57</label><mixed-citation publication-type='journal'>Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. Angiotensin receptor blocker prevented {beta}-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. <source>Hypertension</source><year>2009</year>;<volume>54</volume>:<fpage>1345</fpage>-52.<pub-id pub-id-type='pmid'>19805638</pub-id></mixed-citation></ref><ref id='ref58'><label>58</label><mixed-citation publication-type='journal'>Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. <source>Hypertension</source><year>2009</year>;<volume>54</volume>:<fpage>782</fpage>-7.<pub-id pub-id-type='pmid'>19635982</pub-id></mixed-citation></ref><ref id='ref59'><label>59</label><mixed-citation publication-type='journal'>Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. <source>J Clin Invest</source><year>2007</year>;<volume>117</volume>:<fpage>3393</fpage>-402.<pub-id pub-id-type='pmid'>17965777</pub-id></mixed-citation></ref><ref id='ref60'><label>60</label><mixed-citation publication-type='journal'>Biessels GJ, Kappelle LJ. Increased risk of Alzheimer’s disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? <source>Biochem Soc Trans</source><year>2005</year>;<volume>33</volume>:<fpage>1041</fpage>-4.<pub-id pub-id-type='pmid'>16246041</pub-id></mixed-citation></ref><ref id='ref61'><label>61</label><mixed-citation publication-type='journal'>In’t Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. <source>Neurobiol Aging</source><year>2001</year>;<volume>22</volume>:<fpage>407</fpage>-12.<pub-id pub-id-type='pmid'>11378246</pub-id></mixed-citation></ref></ref-list><notes notes-type='citation-text'><p>Cite this as: <italic>BMJ</italic> 2010;340:b5465</p></notes></back></article></PAPER>